# Adaptimmune Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/adaptimmune-therapeutics

- Industry: Biotechnology
- Headquarters: Abingdon, UK
- Website: www.adaptimmune.com
- Total disclosed funding: $104M
- Latest round: Series A (Sep 25, 2014)
- Investors on record: 12

## About

Adaptimmune Therapeutics PLC is a biotechnology company focused on developing innovative T-cell therapies to target and treat solid tumors, utilizing advanced cell therapy techniques to enhance patient outcomes.Founded in 2008 in Abingdon, UK, Adaptimmune Therapeutics PLC specializes in engineered T-cell therapies aimed at combating solid tumors. The company has raised a total of USD 225.50 mn through funding rounds, including a Private Placement/Follow on on June 1, 2020, which raised USD 225 mn. CEO James Noble leads the firm, which has been involved in five deals to date.Adaptimmune specializes in advanced cell therapy solutions aimed at treating challenging solid tumors. The company’s core offerings center around engineered T-cell therapies, which utilize a patient's own cells to create a targeted immune response against cancer. These therapies, known as Afami-cel, Lete-cel, and Uza-cel, focus on specific cancer antigens and have the potential to transform the treatment landscape for patients with various cancer types. Adaptimmune serves a global clientele, including healthcare providers and research institutions, with a strong presence in markets such as the United States and Europe. The end users of these therapies are patients diagnosed with solid tumors, who benefit from the personalized nature of Adaptimmune's innovative treatments.Adaptimmune generates revenue through its proprietary cell therapy products, which are typically administered in clinical settings by healthcare professionals. The company engages in partnerships and collaborations with various healthcare institutions and pharmaceutical companies, facilitating the distribution and administration of its therapies. Revenue is generated primarily through direct sales to healthcare providers for treatments and participation in clinical trials. For the most recent year 2024, Adaptimmune reported revenue of USD 176.28 mn, with an EBITDA of USD -50.65 mn.Adaptimmune plans to further develop its pipeline of engineered T-cell therapies, aiming to launch new products targeting additional cancer types in the coming years. The company is looking to expand its market presence in Europe and Asia by 2025, leveraging recent funding from the June 2020 deal to enhance R&D and operational capabilities. The recent funding will support clinical trials and product development, positioning Adaptimmune to capitalize on new therapeutic opportunities in the oncology sector.

## Funding rounds

- Series A, Sep 25, 2014, $104M — New Enterprise Associates, OrbiMed Advisors, F-Prime Capital, Wellington Management, Merlin Nexus, Foresite Capital, QVT funds, VenBio, Novo Holdings, University of Oxford, Rock Springs Capital, Ridgeback Capital Management

## Investors

- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series A
- Wellington Management (https://capitalatlas.ai/funds/wellington-management) — Series A
- Merlin Nexus (https://capitalatlas.ai/funds/merlin-nexus) — Series A
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series A
- QVT funds — Series A
- VenBio (https://capitalatlas.ai/funds/venbio) — Series A
- Novo Holdings — Series A
- University of Oxford — Series A
- Rock Springs Capital — Series A
- Ridgeback Capital Management — Series A